Mayne Pharma : Change of Director's Interest Notice

Appendix 3Y

Change of Director's Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Mayne Pharma Group Limited

ABN	76 115 832 963

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Scott Anthony Richards
Date of last notice	2 August 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

	Direct or indirect interest		Direct and indirect
	Nature of indirect interest		Solium Nominees (Australia) Pty Ltd as nominee for
	(including registered		Scott Richards (1)
	holder)		HSBC Nominees (Australia) Limited as nominee for Scott Anthony
	Note: Provide details of the		Richards (2)
	circumstances giving rise to the		HSBC Nominees (Australia) Limited as nominee for Scott Anthony
	relevant interest.
			Richards & Susan Marie Richards (3)
	Date of change		3 Dec 2021
	No. of securities held prior		26,627,692 Ordinary Shares pursuant to Executive Share Loan Scheme (1)
	to change		3,862,906 Ordinary Shares (2)
			1,722,463 Ordinary Shares (3)
			3,681,297 Performance Rights pursuant to Performance Right and Option
			Plan
	Class		Performance Rights
	Number acquired		6,060,606
	Number disposed		Nil
	Value/Consideration		Performance Rights - Nil
	Note: If consideration is non-cash,
	provide details and estimated
	valuation
+ See chapter 19 for defined terms.
			Appendix 3Y Page 1

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after	26,627,692 Ordinary Shares pursuant to Executive Share Loan Scheme (1)
change	3,862,906 Ordinary Shares (2)
	1,722,463 Ordinary Shares (3)
	9,741,903 Performance Rights pursuant to Performance Right and Option
	Plan
Nature of change	Issue of performance rights pursuant to Resolution 6 in the Notice of
Example: on-market trade, off-	Meeting for the Company's 2021 Annual General Meeting.
market trade, exercise of options,
issue of securities under dividend
reinvestment plan, participation in
buy-back

Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract

Nature of interest

Name of registered holder (if issued securities)

Date of change

No. and class of securities to which interest related prior to change

Note: Details are only required for a contract in relation to which the interest has changed

Interest acquired

Interest disposed

Value/Consideration

Note: If consideration is non-cash, provide details and an estimated valuation

Interest after change

Part 3 - +Closed period

Were the interests in the securities or contracts	No
detailed above traded during a +closed period where
prior written clearance was required?
If so, was prior written clearance provided to allow	N/a
the trade to proceed during this period?
If prior written clearance was provided, on what	N/a
date was this provided?

• See chapter 19 for defined terms. Appendix 3Y Page 2